Dana-Farber Cancer Institute, located in Boston, has reached a settlement of $15 million to resolve serious allegations of research fraud. The accusations stem from violations of the False Claims Act occurring between 2014 and 2024, involving false statements related to National Institutes of Health (NIH) research grants.
Dana-Farber’s Research Practices Under Scrutiny
As a prominent cancer treatment and research center, Dana-Farber is known for receiving substantial NIH funding. However, the U.S. Department of Justice (DOJ) discovered that some of its researchers misused these funds. Assistant Attorney General Brett A. Shumate emphasized the importance of integrity in federal funding decisions, stating that the DOJ will actively pursue institutions that violate grant conditions.
Key Allegations Against Dana-Farber
The investigation revealed that Dana-Farber’s researchers published 14 scientific articles that contained misrepresented and duplicate images and data. Specific misconduct included:
- Using the same images to depict different experimental conditions.
- Duplicating images for various testing scenarios.
- Modifying images by rotating or stretching them.
Additionally, a supervising researcher failed to adequately oversee these activities. Some expenditures from NIH grants were also deemed unallowable.
Accountability and Cooperations
Dana-Farber cooperated fully with the investigation. The institute took substantial steps to summarize and disclose relevant information to the government. They voluntarily provided materials without needing a subpoena and accepted responsibility for their actions. As part of the settlement, the institute has committed to implementing remediation measures moving forward.
Whistleblower Involvement
The case includes a whistleblower component, initiated by Sholto David. Under the qui tam provisions of the False Claims Act, he may receive $2.625 million from the settlement for his role in reporting the fraud. The case is officially known as U.S. ex rel. Sholto David v. Dana-Farber Cancer Institute, Inc.
Government Efforts Against Healthcare Fraud
The resolution of this case demonstrates the government’s ongoing commitment to combat healthcare fraud, as highlighted by U.S. Attorney Leah B. Foley. She affirmed the necessity for accurate reporting in scientific research, especially in cancer studies.
For future reports of fraud or misconduct, individuals can contact the Department of Health and Human Services at 800-HHS-TIPS.
